Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Pogue

Showing results (41-50 of 68) with videos related to

Pageof 7
Sort By:
Plos Medicine|December 30, 2006
Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanismKay L Pogue-Geile, Ru Chen, Mary P Bronner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2019
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31Saranya Chumsri, Zhuo Li, Daniel J Serie, et al.
Plos One|September 10, 2016
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target ActivitySarah L Pogue, Tetsuya Taura, Mingying Bi, et al.
Plos One|August 18, 2018
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutationsRekha Pal, Ning Wei, Nan Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2019
Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) TrialsSaranya Chumsri, Daniel J Serie, Zhuo Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2012
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive valuePatrick G Gavin, Linda H Colangelo, Debora Fumagalli, et al.
Nature Cancer|March 17, 2023
Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironmentSayali Onkar, Jian Cui, Jian Zou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
JAMA Oncology|November 5, 2016
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 TrialPatrick G Gavin, Nan Song, S Rim Kim, et al.
Pageof 7

Showing results (41-50 of 68) with videos related to

Sort By:
Pageof 7
Plos Medicine|December 30, 2006
Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanismKay L Pogue-Geile, Ru Chen, Mary P Bronner, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2019
Incidence of Late Relapses in Patients With HER2-Positive Breast Cancer Receiving Adjuvant Trastuzumab: Combined Analysis of NCCTG N9831 (Alliance) and NRG Oncology/NSABP B-31Saranya Chumsri, Zhuo Li, Daniel J Serie, et al.
Plos One|September 10, 2016
Targeting Attenuated Interferon-α to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target ActivitySarah L Pogue, Tetsuya Taura, Mingying Bi, et al.
Plos One|August 18, 2018
Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutationsRekha Pal, Ning Wei, Nan Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2019
Effects of Age and Immune Landscape on Outcome in HER2-Positive Breast Cancer in the NCCTG N9831 (Alliance) and NSABP B-31 (NRG) TrialsSaranya Chumsri, Daniel J Serie, Zhuo Li, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 7, 2015
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trialKatherine L Pogue-Geile, Nan Song, Jong-Hyeon Jeong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 10, 2012
Mutation profiling and microsatellite instability in stage II and III colon cancer: an assessment of their prognostic and oxaliplatin predictive valuePatrick G Gavin, Linda H Colangelo, Debora Fumagalli, et al.
Nature Cancer|March 17, 2023
Immune landscape in invasive ductal and lobular breast cancer reveals a divergent macrophage-driven microenvironmentSayali Onkar, Jian Cui, Jian Zou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 2, 2023
Biomarker Data from the Phase III KATHERINE Study of Adjuvant T-DM1 versus Trastuzumab for Residual Invasive Disease after Neoadjuvant Therapy for HER2-Positive Breast CancerCarsten Denkert, Chiara Lambertini, Peter A Fasching, et al.
JAMA Oncology|November 5, 2016
Association of Polymorphisms in FCGR2A and FCGR3A With Degree of Trastuzumab Benefit in the Adjuvant Treatment of ERBB2/HER2-Positive Breast Cancer: Analysis of the NSABP B-31 TrialPatrick G Gavin, Nan Song, S Rim Kim, et al.
Pageof 7